Invested Advisors Makes New Investment in SPDR S&P Biotech ETF $XBI

Invested Advisors acquired a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 5,441 shares of the exchange traded fund’s stock, valued at approximately $502,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. DHJJ Financial Advisors Ltd. bought a new position in shares of SPDR S&P Biotech ETF during the second quarter worth $25,000. Capital A Wealth Management LLC purchased a new stake in SPDR S&P Biotech ETF in the 2nd quarter worth $26,000. Johnson Financial Group Inc. purchased a new stake in SPDR S&P Biotech ETF in the 2nd quarter worth $31,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of SPDR S&P Biotech ETF during the 2nd quarter valued at about $32,000. Finally, Davis Capital Management purchased a new position in shares of SPDR S&P Biotech ETF during the third quarter valued at about $35,000.

SPDR S&P Biotech ETF Trading Down 2.2%

NYSEARCA:XBI opened at $123.71 on Friday. The company has a market capitalization of $8.27 billion, a P/E ratio of 11.47 and a beta of 0.93. SPDR S&P Biotech ETF has a 12 month low of $66.66 and a 12 month high of $129.12. The business’s 50-day moving average is $119.35 and its 200 day moving average is $102.51.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.